Silence Therapeutics () chief financial officer Rob Quinn and head of business development John Strafford discuss this week's 'transformational' deal they've struck with major .
It's worth US$80mln in cash and investment upfront, plus a further US$400mln in milestone payments and royalties for each disease area targeted.
Using Silence’s small interfering RNA, or siRNA technology, AstraZeneca is looking to initially develop treatments for liver, heart and lung diseases.
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Silence Therapeutics PLC named herein, including the promotion by the Company of Silence Therapeutics PLC in any Content on the Site, the...
FOR OUR FULL DISCLAIMER CLICK HERE